OptimizeRx Corp Reports Strong Q1 Performance, Raises Revenue Guidance Amid Subscription Model Success
OptimizeRx Corp reported strong Q1 2025 performance, with 11% revenue growth and improved EBITDA, leading to raised revenue guidance and a stock target increase to $14.
2 minutes to read